KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Deferred Taxes (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Deferred Taxes data on record, last reported at $30.5 million in Q4 2025.

  • For Q4 2025, Deferred Taxes fell 40.89% year-over-year to $30.5 million; the TTM value through Dec 2025 reached -$510.8 million, down 46.44%, while the annual FY2025 figure was -$510.8 million, 46.44% down from the prior year.
  • Deferred Taxes reached $30.5 million in Q4 2025 per VRTX's latest filing, up from -$235.9 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $148.1 million in Q4 2022 and bottomed at -$237.9 million in Q2 2021.
  • Average Deferred Taxes over 5 years is -$91.3 million, with a median of -$117.2 million recorded in 2023.
  • Peak YoY movement for Deferred Taxes: skyrocketed 453.46% in 2022, then plummeted 821.95% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at -$41.9 million in 2021, then surged by 453.46% to $148.1 million in 2022, then plummeted by 188.45% to -$131.0 million in 2023, then skyrocketed by 139.39% to $51.6 million in 2024, then crashed by 40.89% to $30.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $30.5 million in Q4 2025, -$235.9 million in Q3 2025, and -$113.8 million in Q2 2025.